Back to Newsroom

Singapore’s First Influenza Vaccine Demonstrates Favourable Immunogenicity and Tolerability in Clinical Testing

SINGAPORE and ZURICH, January 29, 2014 — SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ — Singapore’s Agency for Science, Technology and Research (A*STAR) and Switzerland’s Cytos Biotechnology AG today announced that their influenza vaccine (gH1-Qbeta) met its primary endpoint for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the Phase 1 clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent drifted H1N1 strains. The H1N1 influenza vaccine candidate is based on Cytos’ proprietary bacteriophage Qbeta virus-like particle (VLP) technology.